Coherus Biosciences | CHRS - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
AbbVie USD 58.94B 4.03B 2025-12
Acadia Pharmaceuticals USD 0 0 2025-03
Akebia Therapeutics USD 48.25M 609K 2025-12
ALKERMES USD 285.82M 639K 2024-09
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Amgen USD 51.89B 1.88B 2026-03
Baxter International USD 8.62B 852M 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Fujifilm JPY 642.24B 70.37B 2025-12
Gilead Sciences USD 22.13B 6M 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Merck USD 46.67B 77M 2026-03
Myriad Genetics USD 119.9M 400K 2025-12
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.6B 4.5M 2025-12
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 2.03B 193.22M 2025-12
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Teva Pharmaceutical Industries USD 14.02B 971M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Xencor USD 76.48M 11.29M 2025-12
Zoetis USD 9.04B 1.97B 2025-12